Richard Joseph Auchus, MD, PhD

University of Michigan
Division of Metabolism, Endocrine, and Diabetes

Biographical Sketch:
Dr. Richard Auchus earned his bachelor’s degree in Chemistry at the Massachusetts Institute of Technology and his M.D. and Ph.D. in Pharmacology at Washington University. He trained in internal medicine at the University of Iowa and completed his endocrinology fellowship at Wilford Hall USAF Hosptial/UTHSC San Antonio, where he also served in the US Air Force’s medical corps. He performed postdoctoral research and served on the faculty in Pediatrics and Internal Medicine at the University of California, San Francisco. He was an assistant, associate, and full professor at the University of Texas Southwestern Medical Center at Dallas and was acting chief of the Division of Endocrinology and Metabolism and the Division of Translational Research prior to his relocation to the University of Michigan in 2011. He is currently professor of Internal Medicine in the Division of Metabolism, Endocrinology, and Diabetes and Director of the Endocrinology Fellowship Program. Dr. Auchus has authored over 160 journal articles and book chapters, and he has presented at a diverse range of national and international conferences. His group is active in research projects ranging from basic chemical principles of steroid biosynthetic enzymes to clinical and translational investigation in disorders of the pituitary, adrenals, ovaries, and testes that cause hypertension, infertility, and obesity. The common theme of all his work is steroid and sterol biosynthesis and action with an emphasis on human diseases, with collaborations ranging from clinical psychology to basic mechanisms of nematode lifecycles. His clinical interests also focus on adrenal, pituitary, and reproductive diseases that involve disorders of steroid production. He is also active in physician training and education, as well as efforts to improve the health of patients with endocrine diseases.
A Novel CYP17A1 Mutation in a Compound Heterozygote and Response to Mineralocorticoid Receptor Antagonist Therapy
Genomic Approaches to Understanding Primary Aldosteronism
Steroidogenic Factor-1 Antagonist Suppression of Glucocorticoid Synthesis
LB-OR-1 Marked Androgen Reduction in Adult Women With Classic 21-Hydroxylase Deficiency (21OHD) Treated With Abiraterone Acetate (AA) Added to Physiologic Hydrocortisone (HC) and Fludrocortisone (FC)
MC2 Adrenal Nodules
OR06-6 Impaired 17,20-lyase activity in mice lacking cytochrome b5 in testicular Leydig cells